PURPOSE OF REVIEW: Bacillus Calmette-Guérin (BCG) is the standard immune therapy for nonmuscle invasive bladder cancer. A systematic review of published articles regarding BCG treatment of bladder cancer was conducted and a commentary of these is provided to gain a perspective of the current major developments in the field. RECENT FINDINGS: Several BCG strains are utilized worldwide. As the understanding of genetic and phenotypic differences in these strains is elucidated, inquiries into the potential clinical effects of these various strains have been studied. Data suggest that some strains could be more effective than others but further study is needed. Although response to BCG is heterogenous, current clinical practice does not incorporate use of biomarkers to delegate treatment selection. Thus, biomarker prediction is an important area of research in this area. Novel urine and tissue markers show promise in this endeavor. Notable publications also include mechanistic studies showing a role for T cells, natural killer cells, mast cells, and granulocytes in BCG's antitumor efficacy. SUMMARY: Significant developments have occurred in understanding BCG's response and mechanism of action, which remains incompletely understood. Future work includes efforts to create recombinant BCG strains to decrease side effects, repeated instillations, and increase overall efficacy.
PURPOSE OF REVIEW: Bacillus Calmette-Guérin (BCG) is the standard immune therapy for nonmuscle invasive bladder cancer. A systematic review of published articles regarding BCG treatment of bladder cancer was conducted and a commentary of these is provided to gain a perspective of the current major developments in the field. RECENT FINDINGS: Several BCG strains are utilized worldwide. As the understanding of genetic and phenotypic differences in these strains is elucidated, inquiries into the potential clinical effects of these various strains have been studied. Data suggest that some strains could be more effective than others but further study is needed. Although response to BCG is heterogenous, current clinical practice does not incorporate use of biomarkers to delegate treatment selection. Thus, biomarker prediction is an important area of research in this area. Novel urine and tissue markers show promise in this endeavor. Notable publications also include mechanistic studies showing a role for T cells, natural killer cells, mast cells, and granulocytes in BCG's antitumor efficacy. SUMMARY: Significant developments have occurred in understanding BCG's response and mechanism of action, which remains incompletely understood. Future work includes efforts to create recombinant BCG strains to decrease side effects, repeated instillations, and increase overall efficacy.
Authors: Claire Biot; Cyrill A Rentsch; Joel R Gsponer; Frédéric D Birkhäuser; Hélène Jusforgues-Saklani; Fabrice Lemaître; Charlotte Auriau; Alexander Bachmann; Philippe Bousso; Caroline Demangel; Lucie Peduto; George N Thalmann; Matthew L Albert Journal: Sci Transl Med Date: 2012-06-06 Impact factor: 17.956
Authors: E C De Boer; W H De Jong; A P Van Der Meijden; P A Steerenberg; J A Witjes; P D Vegt; F M Debruyne; E J Ruitenberg Journal: Cancer Immunol Immunother Date: 1991 Impact factor: 6.968
Authors: Eviatar Friedlander; Paula Martínez Pascual; Pedro Montilla de Mora; Bartolomé Scola Yurrita Journal: Braz J Otorhinolaryngol Date: 2016-02-06
Authors: Soum D Lokeshwar; Maite Lopez; Semih Sarcan; Karina Aguilar; Daley S Morera; Devin M Shaheen; Bal L Lokeshwar; Vinata B Lokeshwar Journal: Cancers (Basel) Date: 2022-05-24 Impact factor: 6.575
Authors: Neelam Mukherjee; Niannian Ji; Xi Tan; Chun-Lin Lin; Emily Rios; Chun-Liang Chen; Tim Huang; Robert S Svatek Journal: Cancer Med Date: 2021-09-08 Impact factor: 4.452
Authors: Danielle Klinger; Brian L Hill; Noam Barda; Eran Halperin; Ofer N Gofrit; Charles L Greenblatt; Nadav Rappoport; Michal Linial; Hervé Bercovier Journal: Vaccines (Basel) Date: 2021-05-11